KLRK1 and myelodysplastic syndrome: Recently, one new clinical trial (NCT04623944) was registered to determine the safety and tolerability of an experimental therapy known as NKX101 (allogeneic CAR-NK cells targeting NKG2D ligands) in patients with r/r AML, r/r MDS or intermediate (high/very high)-risk MDS.